We have launched! Our experienced salesforce of over 100 reps is bringing #Ohtuvayre (ensifentrine) to doctors and patients throughout the US, working closely with our exclusive network of accredited specialty pharmacies.
Verona Pharma
Biotechnology Research
London, UK 15,102 followers
Developing life enhancing treatments for chronic respiratory diseases
Über uns
Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma's product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. Ensifentrine met the primary endpoint in both ENHANCE-1 and ENHANCE-2 trials demonstrating statistically significant and clinically meaningful improvements in lung function. In addition, ensifentrine significantly reduced the rate of COPD exacerbations in ENHANCE-1 and ENHANCE-2. We are led by a management team with an established track record in the discovery, development and commercialization of respiratory therapies. Verona Pharma is listed on the Nasdaq Global Market in the United States under the ticker symbol VRNA. We are headquartered in London, UK, and have offices in Raleigh and Savannah in the US. For more information, please visit https://www.veronapharma.com.
- Website
-
https://www.veronapharma.com
External link for Verona Pharma
- Industrie
- Biotechnology Research
- Größe des Unternehmens
- 51-200 Mitarbeiter
- Hauptsitz
- London, UK
- Typ
- Öffentliches Unternehmen
- Gegründet
- 2005
- Spezialitäten
- Novel therapies for chronic respiratory diseases , COPD, CF, and Asthma
Standorte
-
Primäre
Wegbeschreibung erhalten
3 More London Riverside
London, UK SE1 2RE, GB
-
Wegbeschreibung erhalten
8045 Arco Corporate Drive
Suite 130
Raleigh, North Carolina 27617, US
-
Wegbeschreibung erhalten
33 Park of Commerce Way
Savannah, Georgia 31405, US
Employees at Verona Pharma
Aktualisierungen
-
Verona’s management team will present a company overview at the Canaccord Genuity Group Inc.'s 44th Annual Growth Conference, today at 1:30 p.m. ET. We look forward to connecting with industry experts and investors about our recently approved therapy. Tune into the webcast: https://bit.ly/4dj0Txe
-
-
Today, we announced our financial results for the second quarter, ended June 30, 2024, and provided an update on the launch of our first commercial product. We are excited for the second half of 2024 as we bring our new treatment to patients in need. Listen to the webcast here: https://bit.ly/3LYfrWQ
-
-
Verona’s management team will be in Boston for the Canaccord Genuity Group Inc. Annual Growth Conference to connect with leaders in the #healthcare and #LifeScience investment community on Ohtuvayre™ (ensifentrine) and other pipeline updates. Contact us here: https://bit.ly/4ehHQEn
-
-
In two weeks, we will announce our financial results for Q2 2024 and host a conference call for the investment community. Tune in to our webcast on August 8th at 9:00 a.m. EDT / 2:00 p.m. BST UK. Details: https://bit.ly/4ddwEHj #COPD #earnings
-
-
June was an exciting month for Verona Pharma as the US FDA approved Ohtuvayre™! We are preparing to launch Ohtuvayre™ (ensifentrine) in the US and look forward to providing updates on our progress. #FDAApproval
-
-
The #FDAApproval of the first inhaled product with a novel mechanism of action for the maintenance treatment of #COPD in over 20 years represents an important advancement for the COPD community. Thank you to all those involved in our clinical trials, and the Verona team for their support, participation and collaboration! More: https://bit.ly/4bnUSxt
-
-
#Bronchiectasis is a chronic condition affecting approx. 370,000 adults in the US, where the lung’s bronchi become permanently damaged. On #WorldBronchiectasisDay, we are raising awareness for non-cystic fibrosis bronchiectasis (NCFB), a disease with no FDA-approved drugs specifically for NCFB. Verona’s investigational drug #ensifentrine is currently in Phase 2 clinical studies for the treatment of NCFB. Learn more about this focus area: https://bit.ly/3z3gVvX
-
-
The recent #FDAApproval of our novel drug marks an important milestone for Verona Pharma and patients with #COPD in the US. Hear from our leaders and other industry experts on the impact this approval could have on disease management.
-
Today, at 8:30 a.m. EDT / 1:30 p.m. BST we will host an investor webcast to discuss the US #FDAApproval of Ohtuvayre™ (ensifentrine). Tune in here: https://bit.ly/4bnUSxt
-